Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

A venetoclax bench-to-bedside story

Nature Cancer volume 2, pages 3–5 (2021)Cite this article

Subjects

Inhibition of the anti-apoptotic protein BCL-2 has emerged as a highly effective treatment for acute myeloid leukemia; approved lower-intensity venetoclax combination therapies are now being rapidly incorporated into an improved standard of care for this cancer. Here we recount an abbreviated history of venetoclax for acute myeloid leukemia, focusing on a selection of key studies along the path from development into the clinic.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: An overview of BCL-2 family proteins and AML.

References

  1. Certo, M. et al. Cancer Cell 9, 351–365 (2006).

    Article  CAS  Google Scholar 

  2. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. Nat. Rev. Drug Discov. 16, 273–284 (2017).

    Article  CAS  Google Scholar 

  3. Oltersdorf, T. et al. Nature 435, 677–681 (2005).

    Article  CAS  Google Scholar 

  4. Roberts, A. W. et al. J. Clin. Oncol. 30, 488–496 (2012).

    Article  CAS  Google Scholar 

  5. Souers, A. J. et al. Nat. Med. 19, 202–208 (2013).

    Article  CAS  Google Scholar 

  6. Pan, R. et al. Cancer Discov. 4, 362–375 (2014).

    Article  CAS  Google Scholar 

  7. Niu, X. et al. Clin. Cancer Res. 22, 4440–4451 (2016).

    Article  CAS  Google Scholar 

  8. Bogenberger, J. M. et al. Leukemia 28, 1657–1665 (2014).

    Article  CAS  Google Scholar 

  9. Konopleva, M. et al. Cancer Discov. 6, 1106–1117 (2016).

    Article  CAS  Google Scholar 

  10. DiNardo, C. D. et al. Blood 133, 7–17 (2019).

    Article  CAS  Google Scholar 

  11. Wei, A. H. et al. J. Clin. Oncol. 37, 1277–1284 (2019).

    Article  CAS  Google Scholar 

  12. Wei, A. H. et al. Blood 135, 2137–2145 (2020).

    Article  CAS  Google Scholar 

  13. DiNardo, C. D. et al. N. Engl. J. Med. 383, 617–629 (2020).

    Article  CAS  Google Scholar 

  14. DiNardo, C. D. et al. Blood 135, 791–803 (2020).

    Article  CAS  Google Scholar 

  15. Zhang, H. et al. Nat. Cancer 1, 826–839 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

C.D.D. and M.Y.K. are funded by US National Institutes of Health/National Cancer Institute grant R01CA235622 (principal investigator, M.Y.K.; 17 June 2019 to 31 May 2024). This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672 and the MD Anderson Cancer Center Leukemia SPORE CA100632.

Author information

Authors and Affiliations

  1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Courtney D. DiNardo & Marina Y. Konopleva

Authors
  1. Courtney D. DiNardo
    View author publications

    Search author on:PubMed Google Scholar

  2. Marina Y. Konopleva
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Courtney D. DiNardo.

Ethics declarations

Competing interests

C.D.D. reports research funding from Abbvie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc and Loxo; advisory/consulting for Abbvie, Agios, Celgene/BMS, Daiichi Sankyo, ImmuneOnc, Novartis and Takeda; and stock options from Notable Labs. M.Y.K. reports research funding from AbbVie, Genentech, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Sanofi, Rafael and Forty-Seven; advisory/consulting for AbbVie, Genentech, F. Hoffmann–La Roche, Cellectis, Stemline Therapeutics, Kisoji and Forty-Seven; and stock options/royalties from Reata Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DiNardo, C.D., Konopleva, M.Y. A venetoclax bench-to-bedside story. Nat Cancer 2, 3–5 (2021). https://doi.org/10.1038/s43018-020-00165-6

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-020-00165-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer